Sök artiklar i SveMed+

Observera: SveMed+ upphör att uppdateras!



Cinacalcet - et nyt medicinsk behandlingsprincip til sekundaer hyperparatyroidisme ved uraemi, parathyroideacancer og primaer hyperparatyroidisme
Engelsk titel: Cinacalcet - a new drug for the treatment of secondary hyperparathyroidism in patients with uraemia, parathyroid cancer or primary hyperparathyroidism Läs online Författare: Vestergaard P ; Rejnmark Nielsen L ; Mosekilde L Språk: Dan Antal referenser: 10 Dokumenttyp: Översikt UI-nummer: 06011336

Tidskrift

Ugeskrift for Laeger 2006;168(1)29-32 ISSN 0041-5782 E-ISSN 1603-6824 KIBs bestånd av denna tidskrift Denna tidskrift är expertgranskad (Peer-Reviewed)

Sammanfattning

Cinacalcet is a new drug with antiparathyroid effects that belongs to the class of calcimimetics. It increases the sensitivity of the calcium-sensing receptor (CaSR) to calcium, thus inducing a decrease in plasma parathyroid (PTH) levels. In patients with uncontrolled secondary hyperparathyroidism due to uremia, cinacalcet has been shown to decrease the levels of PTH even in those optimally treated with calcium and 1-ahydroxylated vitamin D. Cinacalcet decreases plasma calcium and plasma PTH levels in patients with primary hyperparathyroidism or parathyroid cancer.